SERINA THERAPEUTICS INC.
SERNYSE AMERICANTrading Snapshot
- Day Range
- $2.07 – $2.09
- 52-Week Range
- $1.22 – $5.83
- Volume
- $2.67B
- Avg Volume
- $3.55B
- Shares Outstanding
- 15.0M
- Next Earnings
- Nov 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $837,355
- P/E Ratio
- -1.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.29
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −5.2%
Why Investors Own SER
- ✓High-growth profile — revenue up +5.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 29% gross margin and 19% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SERINA THERAPEUTICS INC.
SER
StockOtter · stockotter.spaceAbout SERINA THERAPEUTICS INC.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"
Featuring Serina Therapeutics' CEO - Thursday, September 24, 2026 10M people in the world currently living with Parkinson's disease with no major clinical advances in 50+ years Meet with Serina's CEO Steven Ledger Regist
Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Sees Significant Decline in Short Interest
Serina Therapeutics, Inc. (NYSEAMERICAN:SER - Get Free Report) was the recipient of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 70,094 shares, a d
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
HUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimiza
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2
- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evaluated were consisten
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimiz